U.S. Pharma Stock News

In recent days, Crown Holdings reported strong fiscal 2025 results, with revenue and earnings growth supported by European shipments and favorable currency effects, while Jefferies reaffirmed its positive view citing the company’s advanced Bowling Green manufacturing plant. Beyond headline growth, the emphasis on high-tech, efficient production at Bowling Green underlines how manufacturing quality and innovation are becoming central to Crown’s competitive position. Now we’ll explore how this...

In March 2026, Northern Oil and Gas, Inc. completed a follow-on equity offering of approximately US$200.00 million, issuing 7,207,208 common shares at US$27.75 each and granting underwriters a 30-day option to purchase up to an additional 1,081,081 shares. This sizable capital raise, which increases the company’s share count, highlights management’s willingness to tap equity markets to support its growth and acquisition agenda. We’ll now examine how this sizeable equity issuance, and the...

If you are wondering whether Veralto, at around US$90.20, is offering fair value right now or if the market is mispricing it, this article walks you through what the numbers actually say. The stock has recently been under pressure, with a 7 day return of a 4.4% decline, a 30 day return of a 5.1% decline and a year to date return of an 8.4% decline, adding to a 1 year return of a 7.5% decline. Recent coverage around Veralto has focused on how the newly listed business fits into the broader...

If you are wondering whether Terex shares are still offering value at current levels, you are not alone. This article will walk through what the market price might be implying about the business. The stock last closed at US$59.41, with returns of 8.0% year to date and 49.4% over the past year. However, a 4.3% decline over the last week and a 14.0% decline over the last month shows sentiment has recently cooled. These short term moves sit against a longer backdrop where Terex has also...

Exelixis recently reported quarterly adjusted earnings per share that exceeded expectations, helped by higher Cabometyx volumes and lower operating expenses, while the FDA accepted its New Drug Application for zanzalintinib in metastatic colorectal cancer with a target action date in December 2026. Alongside these results, the company reiterated its 2026 guidance and benefited from multiple upward analyst earnings estimate revisions, underscoring how regulatory milestones and disciplined...

CRH plans to delist its ordinary and preference shares from the London Stock Exchange, subject to shareholder approval. If approved, the company will maintain a sole primary listing on the New York Stock Exchange under the ticker NYSE:CRH. The move is intended to consolidate trading in one market and could affect how different groups of investors access and trade the shares. NYSE:CRH currently trades at $99.82, with the share price showing a 4.1% gain over the past year and a 132.7% return...

NGL Energy Partners LP recently closed a seven-year US$950 million senior secured term loan facility and amended its asset-based revolving credit facility, using the proceeds to repay existing borrowings, repurchase a portion of its Class D Preferred Units, and for general corporate purposes. This refinancing reshapes the partnership’s mix of debt and preferred equity, with the targeted repurchase of about 195,000 Class D units signaling a push for a simpler, more flexible capital...

Crown Castle recently reported Q4 2025 earnings that came in ahead of analyst expectations, with EPS of US$0.67 and revenue of US$1.07 billion, and outlined a plan to sell its small cell and fiber businesses in early 2026 while cutting jobs, repurchasing US$1.00 billion of shares, and repaying US$7.00 billion of debt. This shift toward a more tower-centric business model, paired with management’s confidence in improved 2026–2027 financial metrics, marks a meaningful reshaping of how the...

If you are wondering whether Teradata's current share price offers good value or not, you are in the right place because this article focuses squarely on what the numbers say about the stock. Teradata shares last closed at US$26.58, with a 7 day return of a 5.1% decline, a 30 day return of a 29.8% decline, and a 1 year return of a 17.1% gain, which gives you a sense of both recent setbacks and longer term recovery. Recent attention on Teradata has been shaped by ongoing interest in data and...

FIGS (NYSE:FIGS) is partnering with US lawmakers on the Healthcare is Human Act, a bipartisan federal bill. The proposed legislation would offer tax credits to healthcare professionals working in shortage areas. The effort is aimed at addressing workforce shortages and burnout in critical healthcare settings. FIGS, best known for its premium medical scrubs and apparel, is closely tied to the everyday realities of healthcare workers. By stepping into the policy arena through the Healthcare...

If you are wondering whether Ulta Beauty's share price still makes sense after its recent swings, this article will walk through what the current market tag might be telling you about the stock's value. The shares most recently closed at US$535.72, after a 17.1% decline over the last 7 days and a 21.6% decline over the last 30 days, set against a 49.9% return over the past year. Recent price moves have come alongside ongoing attention on Ulta Beauty's position in the US specialty retail...

Earlier this week, Callaway Golf Company, formed from the merger of Callaway and Topgolf, was hit by the renewed war with Iran, which pushed oil prices back to around US$100 per barrel and stoked concerns about prolonged global inflation and economic disruption. At the same time, worries about Callaway Golf’s below-standard constant currency growth, rising capital needs, and weaker returns on past investments have focused attention on how effectively management can balance expansion with...

Wondering if Symbotic at around US$49.43 is still a compelling opportunity or already pricing in a lot of optimism? This article is going to focus squarely on what the current share price implies about the company’s value. Over the past week the stock returned 1.7%, while the 30 day return was a 15.4% decline and the year to date return was a 23.8% decline, set against a 128.3% return over the last year and 164.0% over three years. Recent coverage around Symbotic has largely focused on its...

If you are wondering whether WSFS Financial at around US$62.72 is still offering value or starting to look fully priced, you are not alone. The stock has had a mixed run recently, with a 0.4% decline over the last 7 days and a 7.3% decline over 30 days, set against stronger returns of 13.9% year to date, 22.1% over 1 year, 68.9% over 3 years and 28.5% over 5 years. Recent coverage has focused on the bank's positioning in its regional markets and how investors are weighing those fundamentals...

Antero Midstream (NYSE:AM) has completed a US$1.1b acquisition of Marcellus midstream assets. The transaction expands the company’s midstream footprint and capacity in a key U.S. natural gas region. Management expects 2026 adjusted EBITDA and free cash flow after dividends to be 8% and 11% higher, respectively, versus prior expectations. The business continues to operate under fixed-fee, take-or-pay contracts that reduce direct exposure to commodity price swings. For you as an investor,...

Diversified Energy recently completed a US$108.40 million follow‑on equity offering at US$14.45 per share, filed a universal shelf registration covering multiple securities, and previously executed a 3,750,000‑share buyback that will be cancelled, all while confirming payment details for its Q3 2025 dividend. Together, these capital actions meaningfully reshape Diversified Energy’s share count and funding flexibility, with EIG’s full exit marking a shift in the company’s shareholder...

Expedia Group (NasdaqGS:EXPE) has integrated PredictHQ data into its platform to track and anticipate fan driven travel linked to major events across North America. The partnership focuses on measuring incoming demand on specific routes and in host cities, including triple digit growth in both international and domestic accommodation spending tied to large events. This data driven approach is intended to help Expedia and its partners adjust targeting, pricing, and inventory management around...

Why fresh analyst coverage matters for Ligand Pharmaceuticals (LGND) Recent coverage initiations from Bank of America Securities and other firms have put Ligand Pharmaceuticals (LGND) in focus, spotlighting its royalty based model, diversified portfolio and earnings outlook. For you as an investor, this kind of attention often acts as a prompt to reassess a stock, not just on sentiment but on how its business model converts into revenue, profits and risk. See our latest analysis for Ligand...

Fresh Del Monte Produce Inc. recently returned as an official sponsor of the Miami Open, offering branded smoothie experiences and prominent in-stadium marketing, while its Senior Vice President and General Counsel Effie D. Silva sold 5,894 shares amid Q4 results showing modest sales growth, strong cash generation, and thin margins. The combination of insider selling, cautious analyst commentary on ongoing margin pressures, and regional demand weakness in Asia has taken on greater importance...

In early March 2026, Amgen announced a US$2.52 per-share second-quarter dividend payable on June 5, 2026, and presented its growth and pipeline outlook at the Leerink Global Healthcare Conference, featuring senior leaders in rare disease and finance. Together with analyst commentary emphasizing MariTide in obesity and the Repatha VESALIUS-CV trial, these updates underscored how Amgen’s expanding portfolio and pipeline execution are shaping investor views amid ongoing biosimilar pressures. We...

What Greenbrier’s recent performance tells you Greenbrier Companies (GBX) has drawn fresh attention after a mixed stretch in its share performance, with a roughly 6% decline over the past month alongside a gain of about 10% in the past 3 months. For investors tracking railcar manufacturing and leasing, the stock’s recent pullback compared with its longer multi year total returns raises questions about how to interpret Greenbrier’s current valuation and earnings profile. See our latest...

United Therapeutics (NasdaqGS:UTHR) published full phase 3 TETON-2 results for Tyvaso in idiopathic pulmonary fibrosis (IPF) in the New England Journal of Medicine. The study reported that inhaled Tyvaso preserved lung function and reduced clinical worsening in IPF patients. The company plans to seek FDA approval to add IPF as a new indication on the Tyvaso label. For you as an investor, this centers on United Therapeutics' core focus on pulmonary diseases, where Tyvaso is already an...

If you are wondering whether Nexa Resources at around US$10.95 is still offering value after its recent run, you are not alone. This article will focus on what the current price might imply. The stock has returned 0.7% over the last 7 days and 24.6% year to date, with a 112.9% return over the past year, even though the 30 day return sits at an 11.6% decline. Recent news flow around Nexa Resources has centered on broader sector sentiment, funding conditions and company-specific operational...

Sabine Royalty Trust (SBR) drew fresh attention after reporting March 2026 production results along with a new cash distribution, giving income focused investors updated data on both operating activity and near term payout levels. See our latest analysis for Sabine Royalty Trust. Those March production figures and the fresh cash distribution land at a time when momentum in Sabine Royalty Trust’s unit price has been building. The 30 day share price return is 5.70%, the year to date share price...